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Progressive supranuclear palsy is a rare parkinsonian disorder with characteristic neuroﬁbrillary pa-
thology consisting of hyperphosphorylated tau protein. Common variation deﬁning the microtubule
associated protein tau gene (MAPT) H1 haplotype strongly contributes to disease risk. A recent genome-
wide association study (GWAS) revealed 3 novel risk loci on chromosomes 1, 2, and 3 that primarily
implicate STX6, EIF2AK3, and MOBP, respectively. Genetic associations, however, rarely lead to direct
identiﬁcation of the relevant functional allele. More often, they are in linkage disequilibrium with the
causative polymorphism(s) that could be a coding change or affect gene expression regulatory motifs. To
identify any such changes, we sequenced all coding exons of those genes directly implicated by the
associations in progressive supranuclear palsy cases and analyzed regional gene expression data from
control brains to identify expression quantitative trait loci within 1 Mb of the risk loci. Although we did
not ﬁnd any coding variants underlying the associations, GWAS-associated single-nucleotide poly-
morphisms at these loci are in complete linkage disequilibrium with haplotypes that completely overlap
with the respective genes. Although implication of EIF2AK3 and MOBP could not be fully assessed, we
show that the GWAS single-nucleotide polymorphism rs1411478 (STX6) is a strong expression quanti-
tative trait locus with signiﬁcantly lower expression of STX6 in white matter in carriers of the risk allele.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Progressive supranuclear palsy (PSP) is a progressive neuro-
degenerative disorder characterized by early postural instability,
supranuclear gaze palsy, and cognitive decline with age at onset
typically between 60 and 65 years and 5.8e5.9 years median time
from disease onset to death (Burn and Lees, 2002; Williams and
Lees, 2009). PSP is a primary tauopathy with widespread tau
pathology mainly deﬁned by hyperphosphorylated tau protein,
neuroﬁbrillary tangles, neuropil threads and characteristic glialute and Department of Mo-
on, WC1N 3BG, UK. Tel.: þ44
ll rights reserved.tau inclusions, astrocytic tufts, and oligodendroglial-coiled bodies
in the white matter (Dickson et al., 2007).
By virtue of its pathology, it is not surprising that PSP risk has
been consistently associated with the H1 haplotype of the tau gene
(MAPT) (Baker et al., 1999; Conrad et al., 1997; Ezquerra et al., 1999)
(for review, see Vandrovcova et al., 2010). While a handful of auto-
somal dominant PSP cases have been described (Rohrer et al., 2011;
Rojo et al., 1999), the majority are sporadic, without evidence of fa-
milial clustering. Furthermore some of the MAPT mutations that
cause familial frontotemporal dementiawithparkinsonism linked to
chromosome 17 (FTDP-17 and/or FTLD-tau) (Hutton et al., 1998;
Spillantini et al., 1998) cause phenotypes resembling PSP
(Choumert et al., 2012; Delisle et al., 1999;Morris et al., 2003; Pastor
et al., 2001; Poorkaj et al., 2002; Rohrer et al., 2011; Ros et al., 2005b;
Rossi et al., 2004; Spina et al., 2008; Stanford et al., 2000).
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associationwith PSPand corticobasal degeneration (CBD)has led to
suggestions of allele-speciﬁc differences in transcription and
alternative splicing of MAPT; both PSP and CBD tau pathology is
predominantly 4-repeat tau (4R-tau), that is, consisting of tau
protein isoformswith 4microtubule-binding domains as a result of
splicing ofMAPTexon 10 (Caffrey et al., 2006, 2008; Chambers et al.,
1999; Luk et al., 2010; Majounie et al., 2013; Takanashi et al., 2002;
Trabzuni et al., 2012). The H1c sub-haplotype within the H1 clade,
which drives the association with PSP and CBD (Pittman et al.,
2005) was shown to be associated with increased transcription
and exon 10 splicing and could thus form the basis of the 4R-tau-
dominant pathology (Myers et al., 2007). Other associated loci have
been suggested on chromosomes (Chr) 1q31.1 (Ros et al., 2005a)
and11p12 (Melquist et al., 2007) aswell as a pV380Lpolymorphism
in parkin (PARK2) (Ros et al., 2008), but these have not been
replicated to date.
In 2011, an international consortium published a genome-wide
association study (GWAS) that included a large majority of patho-
logically proven and clinical PSP cases available in Western Europe
and the United States (Höglinger et al., 2011). This unequivocally
revealed several new associations besides that with MAPT
(Höglinger et al., 2011). The associated single-nucleotide poly-
morphisms (SNPs) clustered at 3 different loci on Chr1q25.3,
Chr2p11.2, and Chr3p22.1; at the syntaxin 6 (STX6), eukaryotic
translation initiation factor 2-alpha kinase 3 (EIF2AK3), and myelin-
associated oligodendrocyte basic protein (MOBP) genes, respec-
tively (Höglinger et al., 2011). In addition to the established role of
tau, the genes implicated by these associations provide tantalizing
suggestions about the cellular pathways and processes that could
be affected in PSP, including intracellular vesicular trafﬁcking,
central nervous system (CNS) myelination and the endoplasmic
reticulum (ER)-mediated cellular response to stress, and abnor-
mally unfolded proteins (Höglinger et al., 2011).
As with all genetic association studies, the next challenge is to
determine the functional underpinnings of these associations and
how their allelic differences inﬂuence risk. In the ﬁrst place, the
strongest associations do not necessarily implicate the nearest
gene, but could point to other genes in the vicinity that are in
linkage disequilibrium (LD). On rare occasions, the associated
SNP(s) are the functional variant(s) by missense change of protein
coding sequences or, by inﬂuencing important gene regulatory
motifs involved in expression or splicing. More frequently, associ-
ated SNPs reside within intronic or intergenic regions with the
possibility that they act at the RNA level, thus affecting gene
expression or they inﬂuence the variety of non-coding RNA genes
such as micro-RNAs or their targets. Therefore, to delineate the
associated region, mapping of LD with the associated SNPs enables
us to short list the candidate genes implicated by the associations
for more detailed sequence analysis for the identiﬁcation of high-
risk variants that could affect protein or gene function. In addi-
tion, the availability of array-based genome-wide gene expression
data for various tissues and multiple brain regions (see Trabzuni
et al., 2011) now enables expression quantitative trait locus
(eQTL) analysis to identify expression and splicing changes that are
inﬂuenced by individual SNP alleles, be they in cis within the same
gene locus or neighboring and distal genes.
The ﬁrst discovery stage of the PSP GWAS included 141
pathologically conﬁrmed PSP cases from the Queen Square Brain
Bank (Höglinger et al., 2011). In this study, we selected 84 of
these cases to further investigate the associated loci by direct
sequencing of the coding sequences of the implicated genes to
identify further causative polymorphisms, including missense
changes. Our primary aim was to determine if any coding vari-
ability underpinned the reported association. A secondary aimwas to identify rarer variants that are key to contributing to
disease risk. Furthermore, we carried out analysis of regional
genome-wide eQTL analysis in genetically characterized control
brains to determine if any of the associated SNPs cause allelic
differences in gene expression that might also explain the asso-
ciation with disease.2. Methods
2.1. Study population
Eighty-four pathologically conﬁrmed PSP cases were screened
in this study, all of which were included in the recent GWAS
(Höglinger et al., 2011) and have genome-wide genotype data.
They were all white, western European origin, and met modiﬁed
NINDS possible or probable criteria (Litvan et al., 1996a) and
diagnosis was conﬁrmed pathologically using standardized
criteria (Dickson et al., 2007; Litvan et al., 1996a, 1996b). All pa-
tients were collected under approved protocols followed by
informed consent and this work was approved by the Joint
Medical Ethics Committee of the National Hospital of Neurology
and Neurosurgery, London.2.2. Genetic analysis
Genomic DNA was extracted from dissected samples (100e200
mg) of human postmortem brain tissue using the Qiagen DNeasy
Blood & Tissue Kit (Qiagen, Manchester, UK). Genotype data for the
3 GWAS-associated SNPs rs1411478 (Chr1q25.3; P(joint): 2.3 
1010), rs7571971 (Chr2p11.2; P(joint): 3.2  1013), and rs1768208
(Chr3p22.1; P(joint): 1.0  1016) were derived from the PSP-GWAS
data (Höglinger et al., 2011).
We sequenced all the coding exons and ﬂanking intronic
regions of the genes that were within the associated haplotype
block (regions of LD of r2 > 0.8 with the GWA associated SNPs).
These were STX6 (exons 2e8), trans-membrane protein 1 gene
(MR1) (exons 2e7), EIF2AK3 (exons 2e17), and MOBP (exons
3e5). Primers for polymerase chain reaction ampliﬁcation of
each exon and immediately ﬂanking introns were designed us-
ing Primer3 (http://frodo.wi.mit.edu/primer3/) and are available
upon request. Exploratory sequencing of puriﬁed polymerase
chain reaction amplicons was carried out in a single direction
and in both directions to conﬁrm any identiﬁed variants. Sanger
sequencing was carried out with the Big Dye Terminator kit (ABI,
Foster City, CA, USA) following standard protocol as recom-
mended by the manufacturer, and run on a 3730 DNA Analyzer
(ABI), followed by analysis with Sequencher 4.9 software (Gene
Codes Corporation, Ann Arbor, MI, USA). The sequences of the
coding and ﬂanking intronic regions were used to identify
disease-associated haplotypes that are in LD with the most
strongly associated SNPs from the GWAS. Chr1 (rs1411478
in intron 4 of STX6): common coding and noncoding variants
in STX6 and MR1 were used to build a haplotype spanning
w70 Kbp. Chr2 (rs7571971 in intron 2 of EIF2AK3): common
coding and noncoding variants in EIF2AK3 were used to build a
haplotype spanning w42.6 Kbp. Chr3 (rs1768208 in intron 2 of
MOBP): only noncoding variants in MOBP could be used to build
a haplotype spanning w32 Kbp. LD was analyzed using Haplo-
view (www.broadinstitute.org/haploview) (Barrett et al., 2005)
and SNAP, the SNP annotation and proxy search program (www.
broadinstitute.org/mpg/snap/index.php) (Johnson et al., 2008)
for HapMap Release 22 SNP data for CEU (Utah residents with
Northern and Western European ancestry from the CEPH
collection). The potential damaging effect of any novel missense
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PolyPhen-2 software (Adzhubei et al., 2010).
2.3. Expression quantitative trait locus analysis
Frozen brain originating from 134 neurologically and neuro-
pathologically control individuals was collected by the Medical
Research Council Sudden Death Brain and Tissue Bank, Edin-
burgh, UK (Millar et al., 2007), and the Sun Health Research
Institute, an afﬁliate of Sun Health Corporation, USA (Beach et al.,
2008). From each individual we analyzed up to 10 brain regions:
cerebellar cortex (CRBL), frontal cortex (FCTX), hippocampus
(HIPP), medulla (speciﬁcally inferior olivary nucleus, MEDU),
occipital cortex (speciﬁcally primary visual cortex, OCTX), puta-
men (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal
cortex (TCTX), and intralobular white matter (WHMT). A detailed
description of the samples used in the study, tissue processing
and dissection is provided in (Trabzuni et al., 2011). All samples
had fully informed consent for retrieval and were authorized for
ethically approved scientiﬁc investigation (Research Ethics
Committee number 10/H0716/3).
Total RNA was isolated from human postmortem brain tissues
using the miRNeasy 96 kit (Qiagen). The quality of total RNA was
evaluated by the 2100 Bioanalyzer (Agilent, Wokingham, UK) and
RNA 6000 Nano Kit (Agilent) before processing with the Ambion
WT Expression Kit and Affymetrix GeneChip Whole Transcript
Sense Target Labeling Assay, and hybridization to the Affymetrix
Exon 1.0 ST Arrays following the manufacturer’s protocols (Affy-
metrix, High Wycombe, UK). Hybridized arrays were scanned on
an Affymetrix GeneChip Scanner 3000 7G and visually inspected
for hybridization artifacts. Further details regarding RNA isola-
tion, quality control, and processing are reported in (Trabzuni
et al., 2011).
All arrays were pre-processed using robust multi-array
average normalization (Irizarry et al., 2003) and log2 trans-
formation in Affymetrix Power Tools version 1.14e3. In each case,
we also calculated the “detection above background” metric.
After re-mapping the Affymetrix probe sets onto human genome
build 19 (GRCh37) and using Netaffx annotation ﬁle Release
31(HuEx-1_0-st-v2 Probeset Annotations), we restricted analysis
to 292,000 probe sets which were annotated to have gene names
according to NCBI reference sequence build 36 and contained at
least 3 uniquely hybridizing probes that were free of common
European (frequency > 1%) SNPs or indels (according to the 1000
Genomes Interim Phase v3, March 2012). Gene-level expression
was estimated for 26,000 genes by calculating the Winsorized
mean (below 10% and above 90%) signal of all probe sets corre-
sponding to each gene. The resulting expression data were
adjusted for brain bank, gender, and batch effects in Partek’s
Genomics Suite v6.6 (Partek Incorporated, USA).
All samples were genotyped on the Illumina Inﬁnium Omni1-
Quad BeadChip and on the Immunochip, a custom genotyping
array designed for the ﬁne mapping of auto immune disorders
(International Parkinson Disease Genomics Consortium et al.,
2011). The BeadChips were scanned using an iScan (Illumina,
Little Chesterford, UK) with an AutoLoader (Illumina, USA).
GenomeStudio v.1.8.X (Illumina) was used for analyzing the data
and generating SNP calls.
After standard quality controls (removal of suspected non-
European descent individuals, samples with call rate <95% and
checks on reported sex status, cryptic relatedness, autosomal het-
erozygosity rate check, monomorphic SNPs or call rate <95%, no
genomic position info or redundant SNPs, p-value for deviation
from Hardy-Weinberg equilibrium < 0.0001, genotyping call rate
<95%, less than 2 heterozygotes present, mismatching alleles with1000 Genomes project even after allowing for strand), imputation
was performed using MaCH (Markov Chain Haplotyping algorithm)
software (Li et al., 2009, 2010) and Minimac (http://genome.sph.
umich.edu/wiki/Minimac) using the European-Caucasian panel of
the 1000 Genomes Project (March 2012: Integrated Phase I haplo-
type release version 3, based on the 2010-11 data freeze and 2012-
03-14 haplotypes). We used the resulting w5.88 million SNPs and
w577,000 indels with good post-imputation quality (Rsq >0.50)
and minor allele frequency of at least 5%.
The quantitative trait locus (QTL) analysis was run for each
expression proﬁle (either exon-level or gene-level) against every
genetic marker (either SNP or indel) in MatrixEQTL (Shabalin,
2012). Subsequent analyses were conducted in R (R Development
Core Team, 2011).
3. Results
3.1. PSP GWAS genes are highly expressed in brain with signiﬁcant
regional variation
We directly sequenced the coding exons and their ﬂanking in-
trons in pathologically conﬁrmed PSP cases and compared minor
allele frequencies (MAFs) of known SNPs with data available from
1000 Genomes (http://browser.1000genomes.org/index.html) and
dbSNP (http://www.ncbi.nlm.nih.gov/SNP/). Candidate gene
sequencing data are detailed in Table 1.
Because most GWAS signals do not appear to act via protein
coding changes, we investigated the possibility that they may
operate by regulating the expression of proximal and/or distal
genes using eQTL analysis. This analysis was performed using
paired gene expression and genotyping data generated by the UK
Brain Expression Consortium (Ramasamy et al., 2013; Trabzuni
et al., 2011, 2012). This data set is based on samples originating
from 134 control individuals of European-Caucasian origin. In all
cases, there was no history of a neurological disorder and control
status was conﬁrmed based on histology and examination by a
senior neuropathologist. The individuals sampled had a mean age
at death of 58 years, male: female sex ratio of 1:2.8, and the modal
cause of death was ischaemic heart disease (44.7%). For each indi-
vidual, up to 10 anatomic brain regions were sampled (total of 1231
arrays) to provide genome-wide expression data. The brain regions
analyzed included those commonly affected in PSP such as the
substantia nigra, putamen, hippocampus, and frontal cortex
(Schoﬁeld et al., 2011; Williams et al., 2007).
Of the 26 genetic variants of interest identiﬁed in this analysis
and the GWAS for PSP, 16 had a MAF of >5% and could be
analyzed within our eQTL data set. We checked each genetic
variant for evidence of regulation of any gene within 1 mB with
particular focus on the effects on STX6, MR1, EIF2AK3, and MOBP.
With this in mind, we demonstrate ﬁrstly the robust expression
of these genes in control human brain with signiﬁcant regional
variation (Fig. 1).
3.2. Chromosome 1q25.3: STX6 and MR1
Sequencing of STX6 (Table 1, Fig. 2A) revealed a novel
missense variant in exon 8 in a single PSP case causing a
Cys236Gly substitution (GenBank accession: CAG46671.1) with a
PolyPhen-2 score (Adzhubei et al., 2010) of 0.999 (probably
damaging; sensitivity: 0.14; speciﬁcity: 0.99). The carrier of this
mutation did not have any reported history, where available, of
PSP or neurodegenerative disorders in direct family members
(grandparents, parents, siblings, and children). No information
was available for extended family. In addition, we identiﬁed 2
known synonymous changes: rs12125196; Glu13Glu, and
Table 1
Summary of the sequencing results for STX6 and MR1 (1q25.3), EIF2AK3 (2p11.2), and MOBP (3p22.1). Each known SNP is listed in the “rs number” column. Novel changes are
indicated in bold. Minor allele frequencies (MAFs) are shown and compared with those of the normal population obtained from 1000 genomes (http://browser.1000genomes.
org/index.html) and dbSNP (http://www.ncbi.nlm.nih.gov/SNP/)
Gene Exon Intron rs number AA change Alleles and/or frequency Minor allele MAF
Our samples 1000 genomes Caucasian and/or
European (dbSNP)
STX6 2 rs12125196 Glu13Glu GG (58/60) GA (2/60) AA (0/60) A 0.017 0.011 0.017e0.025
4 ars1411478 d GG (21/82) GA (44/82) AA (17/82) A 0.475 0.426 0.375e0.473e0.483
7 rs3747957 Asn217Asn TT (14/62) TC (33/62) CC (15/62) T 0.492 0.427 0.473e0.483
8 Novel Cys236Gly TT (57/58) TG (1/58) GG (0/58) G 0.009 NA NA
MR1 2 rs2236412 d TT (64/70) TC (5/70) CC (1/70) C 0.050 0.050 NA
rs75150495 d CC (63/70) CG (4/70) GG (3/70) G 0.070 NA NA
3 rs41268456 Arg31His GG (69/70) GA (1/70) AA (0/70) A 0.007 0.004 NA
rs2236410 His39Ala AA (54/70) AG (16/70) GG (0/70) G 0.114 0.206 0.150
rs3863720 Ser46Ser GG (69/70) GA (0/70) AA (1/70) A 0.014 0.017 0.042
5 rs149433107 Pro203Ser CC (78/79) CT (1/79) TT (0/79) T 0.006 0.001 NA
rs35223984 Asn239Asn CC (74/78) CT (4/78) TT (0/78) T 0.026 0.014 0.033
7 rs3747956 d GG (35/64) GA (23/64) AA (6/64) A 0.273 0.494 0.267e0.302
rs75073791 d GG (62/64) GA (2/64) AA (0/64) A 0.016 0.011 0.050
EIF2AK3 2 rs867529 Ser136Cys CC (31/63) CG (28/63) GG (4/63) G 0.286 0.288 0.267e0.292
2 ars7571971 d CC (36/80) CT (40/80) TT (4/80) T 0.300 0.287 0.267e0.317
3 rs13045 Gln166Arg AA (6/59) AG (25/59) GG (28/59) A 0.313 0.347 0.300e0.343
9 rs141901506 Asp502Asn GG (57/58) GA (1/58) AA (0/58) A 0.009 NA NA
10 rs55791823 Asp566Val AA (59/61) AT (2/61) TT (0/61) T 0.016 0.001 0.002
10 rs6750998 d AA (39/59) AT (15/59) TT (5/59) T 0.212 0.196 0.242e0.258
11 rs1805164 Gln597Gln AA (33/65) AG (26/65) GG (6/65) G 0.292 0.293 0.270e0.325e0.350
13 rs1805165 Ala704Ser GG (3/43) GT (17/43) TT (23/43) G 0.267 0.287 0.267e0.274e0.280e0.292
13 rs4972221 d AA (30/64) AT (25/64) TT (9/64) T 0.336 0.347 0.300e0.317
MOBP 2 ars1768208 d CC (32/82) CT (43/82) TT (7/82) T 0.347 0.349 0.292e0.295e0.317
3 Novel Gln82Lys CC (63/64) CA (1/64) AA (0/64) A 0.008 NA NA
3 rs2233204 d CC (30/68) CT (27/68) TT (11/68) T 0.360 0.196 0.283e0.317e0.327
4 rs552724 d CC (54/69) CT (8/69) TT (6/69) T 0.145 0.210 0.183e0.195
Key: GWAS, genomewide association study; PSP, progressive supranuclear palsy; SNPs, single-nucleotide polymorphisms.
a PSP-GWAS associated SNPs.
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populations. With reference to the GWAS-associated SNP
rs1411478, a cluster of SNPs, including rs3747957 (STX6
Asn217Asn), is in complete LD (r2 ¼ 1) forming an LD block
spanning the 30-half of STX6, from intron 5 to intron 7 (Fig. 2A,
Supplementary Fig. 1A).
In MR1, we identiﬁed 9 known coding and noncoding variants
(Table 1). Five variants are exonic with 3 causing missense changes:
rs41268456; Arg31His, rs2236410; His39Arg and rs149433107;
Pro203Ser, whereas 2 are silent (rs3863720; Ser46Ser and
rs35223984; Asn239Asn; GenBank accession: CAB77667.1). Only
Arg31His had a PolyPhen-2 score of 0.996 (probably damaging;
sensitivity: 0.55; speciﬁcity: 0.98). Four variants are intronic; 2 are
proximal to exons (rs75150495, 8 bp upstream from the 50 end of
exon 3, exon 3(-8), and rs3747956, 3 bp downstream from the 30
junction of exon 7, exon 7(þ3)). The latter SNP had a slightly
decreased MAF in PSP compared with controls (0.273 vs. 0.494
[1000 Genomes]) but was in line with data from dbSNP (0.273 vs.
0.267e0.302) (Table 1); the MAFs for the other SNPs were com-
parable with the control populations.
Interestingly, the STX6 rs1411478, is the sole GWA poly-
morphism in this study that displayed strong evidence as an
eQTL. Stratifying messenger RNA (mRNA) levels by genotype of
this SNP, we found very strong evidence for the association be-
tween the risk allele A and decreased expression of STX6 (as
measured using Affymetrix exon arrays, transcript ID 2446567).
This association is evident in white matter (p ¼ 1.80  109) but
not in other brain regions in the UK Brain Expression Con-
sortium data set (Fig. 3, Supplementary Fig. 2). We also inves-
tigated the genomic region around rs1411478 for other SNPs
capable of regulating STX6 expression in white matter and
considered all SNPs (genotyped and imputed) within 1 Mb of the
transcription start and stop site for this gene (Fig. 3C) withoutidentifying any further strong and signiﬁcant eQTL signal in this
genomic region.
3.3. Chromosome 2p11.2: EIF2AK3
We identiﬁed several known coding and non-coding variants in
EIF2AK3 (Table 1, Fig. 2B), two of which are intronic; 1 rs6750998,
located just 6 bp downstream from the 30-end of exon 10 (exon
10(þ6)). We also identiﬁed 6 exonic variants, including 5 that
cause missense changes (rs867529; Ser136Cys, rs13045; Gln166Arg,
rs141901506; Asp502Asn, rs55791823; Asp566Val, rs1805165;
Ala704Ser) and 1 silent (rs1805164; Gln597Gln). Amino acid
numbering for EIF2AK3/PERK is with reference to NCBI reference
sequence: NP_004827.4. PolyPhen-2 scores predicted all missense
variants to be benign besides Asp566Val with a score of 0.993
(probably damaging; sensitivity: 0.7; speciﬁcity: 0.97). The MAF
for rs55791823 (Asp566Val) is increased in the PSP cohort
compared with 1000 Genomes and dbSNP data for a European-
Caucasian normal population (CEU) where the minor allele is
very rare (0.016 vs. 0.001 and 0.002, respectively; Table 1). The
other EIF2AK3 SNPs did not differ from the 1000 Genomes or
dbSNP data.
Fig. 2B and Supplementary Fig. 2B illustrate LD structure of the
associated EIF2AK3 region. The GWA SNP rs7571971 is in almost
complete LD with rs867529; Ser136Cys (D’ ¼ 1, r2 ¼ 0.95) and
rs13045; Gln166Arg (D’ ¼ 1, r2 ¼ 0.81). The SNPs rs7571971 and
rs867529 are in almost complete LD with rs1805165; Ala704Ser
(D’ ¼ 1, r2¼ 0.88; D’ ¼ 1, r2¼ 0.94, respectively), whereas rs13045 is
in almost complete LD with the intronic rs4972221 (D’ ¼ 1, r2 ¼
0.92), reﬂecting, however, the exact same LD pattern as in the
normal population (www.broadinstitute.org/mpg/snap/index.php).
Gene and exon level expression analysis did not show any sig-
niﬁcant QTL associations.
Fig. 1. Regional distribution of (A) STX6, (B) MR1, (C) EIF2AK3, and (D) MOBP mRNA expression: box plot of mRNA expression levels for 10 brain regions, based on microarray
experiments and plotted on a log2 scale (y-axis). These plots show the variation in gene transcript expression across 10 brain regions: the frontal cortex (FCTX, n ¼ 127), temporal
cortex (TCTX, n ¼ 119), occipital cortex (speciﬁcally primary visual cortex, OCTX, n ¼ 129), hippocampus (HIPP, n ¼ 122), thalamus (THAL, n ¼ 124), cerebellum (CRBL, n ¼ 130),
substantia nigra (SNIG, n ¼ 101), putamen (PUTM, n ¼ 129), medulla (speciﬁcally inferior olivary nucleus, MEDU, n ¼ 119), and intralobular white matter (WHMT, n ¼ 131). Whiskers
extend from the box to 1.5 times the inter-quartile range. Abbreviation: mRNA, messenger RNA.
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The MOBP gene revealed one novel missense mutation
(Gln82Lys) with a PolyPhen-2 score of benign. The carrier of this
mutation did not have any reported history, where available, of
PSP or neurodegenerative disorders in direct family members
(grandparents, parents, siblings, and children). No information
was available for extended family. We also identiﬁed 2 known
intronic variants (rs2233204 and rs552724). Amino acid
numbering for MOBP is with reference to GenBank accession
BAA05660.1. The MAFs of the 2 intronic SNPs are overallcomparable with 1000 Genomes and European-Caucasian pop-
ulations (Table 1).
LD analysis did not reveal any LD block within our PSP cohort
(Supplementary Fig. 3), whereas the HapMap CEPH Utah data
relative to the GWAS associated SNP rs1768208 revealed a cluster
of SNPs in high LD (r2 > 0.8) spanning a region of w25.5 Kb
spanning the 50 half of the gene from, including the ﬁrst 2 non-
coding exons, but excluding the coding exons (Supplementary
Fig. 1C). This could implicate 50 regulatory regions, including
the MOBP promoter. However, expression analysis did not reveal
any gene or exon level QTL associations.
Fig. 2. Polymorphisms and linkage disequilibrium at the chromosome 1q25.3 (A) and 2p11.2 loci (B): relative positions of genes and polymorphisms with chromosomal co-ordinates
(Mb; genome build hg19/GRCh37) at top. Arrows below gene symbols indicate direction of transcription. In each box the r2 value between 2 SNPs is shown with ranges that vary
between 0 and 0.99. Any value r2 > 0.8 is suggestive of LD. * GWAS associated SNP. Red line indicates linkage disequilibrium plots from CEPH Utah data for northern and/or western
European-Caucasian population regions (r2 > 0.8) (also see Supplementary Fig. 1). Abbreviations: GWAS, genomewide association study; LD, linkage disequilibrium; SNP, single-
nucleotide polymorphism.
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Fig. 3. Evidence for a single eQTL signal associated with the PSP risk SNP rs1411478. (A) Box plot showing the distribution of STX6 gene-level mRNA expression across four brain
regions, white matter (WHMT), frontal cortex (FCTX), putamen (PUTM), and cerebellar cortex (CRBL). Whiskers extend from the box to 1.5 times the inter-quartile range. (B) STX6
gene-level mRNA expression stratiﬁed by the genotypes of the PSP risk SNP rs1411478 in WHMT, FCTX, PUTM, and CRBL. The eQTL p-values are given on the last x-axis. (C) Regional
association plot illustrating the expression quantitative trait loci (eQTL) around the gene STX6 in WHMT. The PSP risk SNP rs1411478 is shown in purple and the LD measures are with
respect to this SNP. Abbreviations: LD, linkage disequilibrium; PSP, progressive supranuclear palsy; SNP, single-nucleotide polymorphism.
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4.1. PSP and the MAPT locus
Tau has long held pre-eminence in PSP contributing to its deﬁ-
nition as a primary tauopathy. This is reinforced by the robustgenetic association with theMAPT H1 haplotype (Baker et al., 1999;
Conrad et al., 1997; Cruchaga et al., 2009; Ezquerra et al., 2011;
Pittman et al., 2005), with the recent GWAS showing an odds ra-
tio >5 (P(joint) ¼ 1.5  10116) (Höglinger et al., 2011). The identiﬁ-
cation of a sub-haplotype of H1, namely H1c, and a crucial SNP,
rs242557, within a downstream repressor domain in the MAPT
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provided evidence that the basis of the association with PSP lies in
allelic differences in gene expression (Myers et al., 2007).4.2. Beyond tau
The recent PSP-GWAS revealed a surprising number of robust
genome-wide signiﬁcant associations that implicate novel loci and
pathways that contribute to disease pathogenesis (Höglinger et al.,
2011). With this work, we used a combination of direct sequencing,
and haplotype and eQTL analysis to ﬁne map the loci highlighted by
the genome-wide association study (Höglinger et al., 2011) with the
aim of better understanding how these loci could contribute to PSP
pathogenesis.4.3. Chromosome 1q25.3
At this locus, the associated SNPs are clustered over the STX6
gene and to a lesser extent, the MR1. We demonstrate that the
GWAS risk allele rs1411478-A is an eQTL associated with signiﬁ-
cantly lower expression levels of STX6 in white matter but not
any other brain regions (p ¼ 1.80  109) (Fig. 3). In fact, the
GWAS SNP, rs1411478 and rs3747957 (Asn217Asn) in STX6 exon 7,
are in a group of multiple SNPs that are in complete LD (r2 ¼ 1),
deﬁning an LD block of w14 Kb (Fig. 2A and Supplementary
Fig. 1A). This region spans intron 5, exons 6 and 7, and most of
the long intron 7. ENCODE tracks (Rosenbloom et al., 2012) for
intron 7 indicate a region, relatively conserved in mammals, that
is featured by DNAseI hypersensitivity clusters, histone 3 acety-
lated at lysine 27 (H3K27Ac), and binding of multiple transcrip-
tion factors from ChIP-seq data. The epigenetic marks are
indicative of gene enhancers (Creyghton et al., 2010) that could
interact with the distant promoter by the formation of chromatin
loops and determine tissue-speciﬁc expression programs during
development (Ong and Corces, 2011).
It is an intriguing possibility that SNPs in this domain that are
in LD with the GWA SNP exert an allele-speciﬁc effect on STX6
expression determined by brain region with the observed eQTL
for white matter. Tau pathology has been described in white
matter of PSP brains, with overexpression of 4R-tau protein iso-
forms in the sub-cortical regions and brain stem (Zhukareva
et al., 2006), and vacuolation with glial inclusions as a conse-
quence of adjacent gray cellular loss and downstream effects of
tau pathology, respectively (Armstrong, 2013). From a functional
perspective, STX6 mediates vesicle fusion in diverse transport
processes of the exo- and endocytic pathways (Jung et al., 2012)
and is mostly involved in late stages of the secretory process
(Teng et al., 2001; Wendler and Tooze, 2001). STX6, like the rest
of the STX family of proteins, contains a functional soluble N-
ethylmaleimide-sensitive factor-attachment protein receptor
(SNARE) domain that is responsible for binding to homologue
SNARE domains of other SNARE-proteins to direct the transfer of
cargo from vesicles to target membranes. Several cell-type spe-
ciﬁc functions have been mooted (for review, see Jung et al.,
2012) including nerve growth factor-dependent neurite
outgrowth (Kabayama et al., 2008). It would be intriguing to
speculate that the reduction of STX6 expression speciﬁcally in
white matter associated with PSP risk could be a contributor to
the characteristic white matter involvement in PSP, including
oligodendroglial tau pathology and/or myelination defects
because of impairments in intracellular protein triage and
transportation. A possible role of dysmyelination is strongly
supported by the involvement of MOBP (see the following
details).Direct sequencing of STX6 coding exons revealed a single novel
missense mutation in STX6, Cys236Gly, with a Polyphen-2 score of
0.999 (probably damaging) in a solitary PSP case, without any
reported family history. Although this mutation seems extremely
rare and unlikely explains the association with PSP at this locus in
our cohort, functional studies are warranted to assess its patho-
genicity and whether it could affect and impair STX6 function.
MR1 screening identiﬁed one missense change rs41268456;
Arg31His in the conserved extracellular a1 ligand-binding
domain (Abos et al., 2011) and has a PolyPhen score of 0.996
(probably damaging) but is very rare with a single heterozygote
in the PSP cases and comparable MAFs for PSP (0.007) and 1000
Genomes controls (0.004). Because of the lack of LD between the
GWA SNP, rs1411478 and the variants we identiﬁed in MR1 and
the absence of any signiﬁcant gene-speciﬁc QTLs, it is less
plausible that MR1 is responsible for the observed association of
this locus with PSP.
4.4. Chromosome 2p11.2
EIF2AK3 codes for the eukaryotic translation initiation factor
2-alpha kinase 3, also known as protein kinase R-like endo-
plasmic reticulum kinase (PERK), a type-I transmembrane protein
in the ER and plays a key role in the unfolded protein response
(UPR). UPR is initiated during ER stress when accumulation of
unfolded protein in the ER lumen exceeds the capacity of ER-
associated degradation (Imrie and Sadler, 2012; Mori, 2009;
Rutkowski and Kaufman, 2004). There is mounting evidence
that dysregulation of UPR or chronic ER stress is a fundamental
process in neurodegenerative disorders associated with insoluble
protein aggregate formation (Matus et al., 2011) and UPR
impairment plays a critical role in the development of tauo-
pathies in that activated UPR enhances tau phosphorylation tau
contributing to the formation of neuroﬁbrillary tangles (Fu et al.,
2010; Nijholt et al., 2012; Park et al., 2009; Resende et al., 2008).
UPR is activated in PSP brain regions most affected by tau pa-
thology, as well as in Alzheimer’s disease and the tau variants of
FTLD (Hoozemans et al., 2009; Nijholt et al., 2012; Stutzbach et al.,
2013). Activated phospho-PERK colocalizes in neurons with path-
ologically phosphorylated tau with suggestion that UPR activation
may be an early event in tau pathogenesis (Hoozemans et al., 2009;
Stutzbach et al., 2013).
More recently, it was shown that speciﬁc inhibition of PERK
kinase activity prevented disease development in a mouse model
of clinical prion disease (Moreno et al., 2013). This neuro-
protective mechanism occurs independently and downstream to
the process of prion propagation and aggregation (Moreno et al.,
2013), and noting the activation of UPR in the tauopathies, it is
possible that PERK inhibition could present as a therapeutic
target in neurodegenerative tauopathies and proteopathies in
general.
We identiﬁed rs5579182 (Asp566Val), affecting a conserved
residue in the cytoplasmic domain, next to the kinase domain of
PERK, a heterozygous change in 2 of 61 cases and was predicted
being probably damaging. The MAF of this variant has a higher
frequency compared with 1000 Genomes and European-Caucasian
population data from dbSNP (0.016 vs. 0.001 and 0.002; Table 1)
but, for statistical comparison, needs to be studied in larger cohorts.
The GWAS SNP rs7571971 belongs to a region of LD (r2 > 0.8)
extending to w72 kb that spans most of the EIF2AK3 gene
(Stutzbach et al., 2013) (Supplementary Fig. 1B). This includes
the coding SNPs rs867529; Ser136Cys, rs13045; Gln166Arg and
rs1805165; Ala704Ser and the intronic, rs4972221 resulting in the
functional coding haplotypes: A: Ser136-Arg166-Ser704; B: Cys136-
Gln166-Ala704, and D: Ser136-Gln166-Ser704 (Liu et al., 2012).
Table 2
Functional haplotypes associated with the EIF2AK3 locus (2p11.2). Haplotype B has been associated with activation of the UPR processes (Liu et al., 2012) and increased risk of
developing PSP (Stutzbach et al., 2013). The frequency of the B haplotype (bold) in our PSP cohort overlaps with that identiﬁed on other PSP cohorts (Stutzbach et al., 2013)
Haplotype SNP and/or amino acid change Haplotype frequency per study
rs867529/(Ser136Cys) rs7571971a rs13045/(Gln166Arg) rs1805165/(Ala704Ser) HapMap CEU Liu et al Stutzbach et al Our study
A C/(Ser) C G/(Arg) T/(Ser) 0.646 0.676 0.645 0.661
B G/(Cys) T A/(Gln) G/(Ala) 0.294 0.311 0.288 0.287
C C/(Ser) C G/(Arg) G/(Ala) / 0.013 0.001 0.011
D C/(Ser) C A/(Gln) T/(Ser) 0.029/0.016 / 0.061 0.033
Key: GWAS, genomewide association study; PSP, progressive supranuclear palsy; SNP, single-nucleotide polymorphism; UPR, unfolded protein response.
a PSP-GWAS associated SNP.
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Caucasians (CEU) whereas haplotype D (0.029) is rare and
haplotype B was shown to be associated with lower bone min-
eral density (Liu et al., 2012) (Table 2). More recently, the GWAS
SNP rs7571971 associated minor T-allele was shown to be in
complete LD with haplotype B, whereas the major C-allele did
segregate with haplotypes A and D (Table 2) in a cohort of about
w1000 of the pathologically conﬁrmed PSP cases including
those in this study (Stutzbach et al., 2013). Although our study
population was relatively small (n ¼ 84), implying a decrease in
the power of association analysis, when comparing the fre-
quencies of the sub-haplotypes associated with EIF2AK3, the
results for our cohort were in line with those of Stutzbach et al.
(2013), especially in the case of haplotype B (0.287 vs. 0.288)
(Table 2), which was suggested bearing risk for PSP because of
increased activity of EIF2AK3 (Liu et al., 2012).
The lack of signiﬁcant gene or exon level QTLs for EIF2AK3 is
supported by Liu et al. (2012), who showed no haplotype-speciﬁc
EIF2AK3 mRNA differences in lymphoblastoid cell lines. However,
cell lines with haplotype B showed increased sensitivity to
thapsigargin-induced ER-stress as measured by increase in
phosphorylated eIF2a levels (Liu et al., 2012), suggesting different
functionality of the coding haplotypes. This could be because of
impaired activity of the associated haplotype B compared with
the major allele, haplotype A (Ser136-Arg166-Ser704) that is
completely conserved in mammals. The Ser136 and Arg166 resi-
dues reside in the lumenal domain of the ER and could thus have
a role in recognizing the unfolded proteins.4.5. Chromosome 3p22.1
MOBP encodes the small myelin-associated oligodendrocyte
basic protein that is the third most abundant protein in CNSmyelin.
Like myelin basic protein, it is small, basic, and localized to compact
myelin, preferentially in the major dense lines with a role in
compaction and normal arrangement of the radial component of
myelin (Yamamoto et al., 1994, 1999; Yoshikawa, 2001). RatMobp is
subject to complex alternative splicing, including the use of alter-
nate exons and 50 and 30 splice sites resulting in at least 5 isoforms,
all sharing a 68-residue amino terminus (McCallion et al., 1999;
Montague et al., 1998) that are targeted to different subcellular
organelles including the mitochondria (Montague et al., 2005).
Multiple mRNAs and expressed sequence tags suggest similar
complexity of human MOBP, with alternate splicing and alternate
exon and splice site usage. Alternative splicing of coding exons re-
sults in 2 protein isoforms of 181 and 83 residues, both sharing the
69-residue amino-terminal domain, whereas the larger isoform has
an unusual proline-rich carboxy-terminal domain with 4 perfect
PRSPPRSERQ repeats (Yamamoto et al., 1994) with a possible
structural role in stabilizing the multilayered structure of
the myelin sheath in the CNS (Yamamoto et al., 1994). More recent
work implicates MOBP with other myelin proteins as primaryantigens in the autoimmune response in multiple sclerosis
(Kaushansky et al., 2010).
Our genetic screening revealed a novel missense variant,
Gln82Lys (1/63, heterozygous change) in the proline-rich domain
of the larger isoform. It is predicted to be benign. We also iden-
tiﬁed 2 common intronic variants (Table 1). Relative to the GWAS
SNP, rs1768208, several SNPs spanning the 50-half of the gene,
including the ﬁrst non-coding exon, are in LD (r2 > 0.84)
(Supplementary Fig. 1C) but, neither of the noncoding SNPs we
identiﬁed are in this LD block. Expression analysis both at the
transcription and splicing level did not show and signiﬁcant QTLs.
Our data thus did not show evidence implicating any functional
underpinnings of the association of MOBP with PSP. However,
oligodendroglial tau pathology in the form of coiled bodies is
characteristic for PSP. The latter occur with tau aggregates
appearing as thread-like processes in oligodendrocytic processes
ensheathing damaged axons. Some of these processes in white
matter are found within both the inner and outer surfaces of
myelin sheaths, corresponding to the inner and outer loops of
oligodendrocytes (Dickson, 1999; Ikeda et al., 1994; Komori,
1999). This suggests dysfunction or a reactive response of the
oligodendrocytes that could be linked to MOBP via myelination
defects.5. Conclusion
The recent GWAS conﬁrmed the robust association of the MAPT
locus with PSP with an odds ratio around 5.4 (Höglinger et al.,
2011). Several studies have shown allele-speciﬁc differences in
MAPT transcription and splicing with FTDP-17/FTLD-tau mutations
at exon 10, and it is clear that imbalances in the 4R-tau/3R-tau ratio
can directly lead to neurodegeneration.
The novel loci provide tantalizing glimpses of crucial cellular
pathways, including intracellular vesicular transport and fusion
to host organelles, the cell’s response to accumulation of abnor-
mally unfolded or misfolded proteins and CNS myelination that, if
defective, could lead to PSP pathogenesis. Although we did not
identify any overt coding or regulatory polymorphisms that
explain the associations, the genome-wide associated SNPs are in
regions of strong LD that completely overlap with the STX6,
EIF2AK3, and MOBP genes. This reiterates these genes as the
carriers of the associated risk and suggests that the functional
underpinnings of these associations could be in intronic, regu-
latory regions, including transcriptional enhancers or non-coding
genes associated with these loci. For example, the STX6 risk allele
correlates with transcription in white matter and could have a
bearing on white matter degeneration and tau pathology. Simi-
larly, the EIF2AK3 features three coding haplotypes with associ-
ation with PSP suggesting functional differences in the protein
variants (Liu et al., 2012; Stutzbach et al., 2013) whereby, UPR
activation acts not as a protective response but rather increases
risk of PSP. Not least, MOBP is mainly expressed in white matter
R. Ferrari et al. / Neurobiology of Aging 35 (2014) 1514.e1e1514.e121514.e10and there is evidence of white matter involvement in PSP as well
as tau pathology affecting white matter. Further studies are
needed to conﬁrm, support, and expand these possibilities.
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